Logo

IMCC

IM Cannabis Corp.

IMCC

IM Cannabis Corp. • NASDAQ
$1.82 ▲ 3.41% (+0.06)
Market Cap $5.62 M
52w High $7.12
52w Low $0.93
Dividend Yield 0%
P/E -3.79
Volume 39.28K
Outstanding Shares 3.09M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $13.851M ▲ $6.884M ▲ $-3.651M ▼ -26.359% ▼ $-0.75 ▼ $-3.733M ▼
Q2-2025 $12.696M ▲ $3.775M ▲ $-309K ▼ -2.434% ▼ $-0.095 ▼ $2.007M ▲
Q1-2025 $12.5M ▼ $3.29M ▼ $275K ▲ 2.2% ▲ $0.089 ▲ $621K ▲
Q4-2024 $13.335M ▼ $22.366M ▲ $-1.011M ▼ -7.582% ▼ $-0.43 ▼ $-1.068M ▼
Q3-2024 $13.883M $2.195M $-922K -6.641% $-0.41 $-502K

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $1.182M ▲ $44.332M ▲ $40.029M ▲ $3.963M ▲
Q2-2025 $794K ▼ $41.068M ▼ $37.007M ▼ $3.522M ▼
Q1-2025 $1.389M ▲ $44.934M ▲ $41.761M ▲ $5.324M ▲
Q4-2024 $863K ▼ $39.188M ▼ $36.042M ▼ $5.243M ▼
Q3-2024 $1.958M $44.635M $40.425M $5.954M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $-3.651M ▼ $-3.498M ▼ $-1.097M ▼ $6.095M ▲ $388K ▲ $-3.502M ▼
Q2-2025 $-194K ▼ $-474K ▼ $19K ▲ $45K ▲ $-595K ▼ $-478K ▼
Q1-2025 $175K ▲ $4.463M ▲ $0 ▼ $-2.872M ▼ $526K ▲ $4.463M ▲
Q4-2024 $-1.213M ▼ $-4.199M ▼ $2K ▲ $3.847M ▲ $-1.095M ▼ $-4.229M ▼
Q3-2024 $-1.082M $2.754M $-74K $-665K $1.258M $2.68M

Five-Year Company Overview

Income Statement

Income Statement IM Cannabis is still a very small, loss‑making business. Sales have been roughly flat over the past few years, with only modest growth and no clear breakout. The company does earn a positive gross margin on what it sells, but this margin is not nearly enough to cover overhead, so operating losses have been recurring every year. There was one especially heavy loss year in the recent past, likely linked to write‑downs and restructuring as the company exited less profitable markets. Since then, losses have narrowed, but the business is still not consistently profitable. Earnings per share look very volatile, in part because of large reverse stock splits and past impairments, which can make the headline figures look worse and harder to interpret. Overall, the income statement shows a company that has stabilized somewhat but has not yet demonstrated a reliable path to steady profits.

Balance Sheet

Balance Sheet The balance sheet has become much smaller and leaner over time. Total assets have shrunk significantly from earlier years, reflecting divestments, restructuring, and a narrower geographic focus. Cash levels are very thin, which limits the company’s safety cushion and flexibility. Debt is present but not huge in absolute terms; the bigger concern is that both equity and the asset base are now quite small, so there is less room to absorb future setbacks. The strong equity position visible a few years ago has been largely used up through losses and restructuring. Overall, the balance sheet looks fragile: it is cleaner and simpler than before, but also more exposed to any operational or regulatory shocks.

Cash Flow

Cash Flow Cash flow from operations has been consistently negative, but the scale of the cash burn has come down over time. Recent figures suggest the business is hovering close to cash break‑even, which is an improvement from earlier, more painful years. Capital spending has been minimal, indicating a focus on preserving cash rather than aggressively expanding capacity. Free cash flow remains slightly negative, meaning the company still depends on outside funding, cost cuts, or working‑capital adjustments to keep going. Any slip in sales, pricing, or collection of receivables could quickly push cash outflows higher, so liquidity management remains a key risk area.

Competitive Edge

Competitive Edge IM Cannabis has carved out a focused niche in medical cannabis, mainly in Israel and Germany. In Israel, it has an integrated setup that runs from supply through to pharmacies and online channels, supported by a recognized brand built over many years. In Germany, it benefits from early entry into a large and regulated medical market, using its licensed facilities and logistics capabilities as a service platform for itself and others. Its competitive strengths are depth in medical cannabis, patient relationships, and an emphasis on quality and compliance. However, the broader cannabis industry is crowded, highly regulated, and subject to price pressure. Many rivals are larger, better capitalized, and able to absorb regulatory or market shocks more easily. IM Cannabis’s sharper geographic focus and exit from Canada show discipline, but also underline its limited scale and dependence on a few core markets for growth and survival.

Innovation and R&D

Innovation and R&D Innovation at IM Cannabis is less about patents and more about how it uses data and technology. The company highlights years of proprietary patient data, a data‑driven approach to product development, and technology to automate and monitor cultivation, such as its automatic trimming system. These efforts are aimed at consistent quality and products tailored to specific medical needs. The partnership with the Technion and the IMC Venture platform suggests a serious, science‑oriented R&D mindset, with work on specialized strains and potential clinical applications. The reported plan to acquire a majority stake in a quantum computing bio‑data company is a bold, high‑risk move. If executed well, it could deepen its capabilities in personalized medicine and analytics; if not, it could distract management and strain already limited financial resources. Overall, the innovation story is ambitious and differentiated, but its commercial payoff is still largely unproven.

Summary

IM Cannabis is a small, medically focused cannabis company in the middle of a strategic reset. It has narrowed its footprint to Israel and Germany, where it has brand recognition, a vertically integrated setup, and a data‑centric approach that could support specialized, higher‑value products. Financially, the company has moved from heavy restructuring and large losses toward a more stable, but still fragile, state. Revenue remains modest, profitability has not yet been achieved, and the balance sheet and cash position offer only a thin buffer against surprises. The long‑term opportunity rests on turning its medical focus, data assets, and partnerships into sustainable, profitable growth, and on managing the leap into more advanced technologies like quantum bio‑data without overreaching. Execution risk, regulatory risk, and funding constraints all remain significant, so the story is one of potential upside tempered by a high degree of uncertainty and financial vulnerability.

NEWS

November 13, 2025 · 9:00 AM UTC

IM Cannabis Reports Third Quarter 2025 Financial Results

Read more

November 6, 2025 · 7:00 AM UTC

IM Cannabis to Report third Quarter 2025 Financial Results on Thursday, November 13th at 9:00am ET

Read more

October 29, 2025 · 4:01 PM UTC

IM Cannabis Announces CFO Departure

Read more

October 23, 2025 · 9:11 AM UTC

IM Cannabis Signs Non-Binding Term Sheet to Acquire 60% Stake in Innovative Quantum Computing Bio Data Company for Up to $54 Million

Read more

September 16, 2025 · 6:07 AM UTC

IM Cannabis Announces Board Changes and Strategic Decision to Identify Additional Business Opportunities

Read more